INT176588

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.78
First Reported 2004
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 27
Total Number 29
Disease Relevance 16.37
Pain Relevance 0.81

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cell proliferation (ERBB2) signal transduction (ERBB2) plasma membrane (ERBB2)
nucleus (ERBB2) cytoplasm (ERBB2)
Anatomy Link Frequency
brain 1
MCF-7 1
ERBB2 (Homo sapiens)
Pain Link Frequency Relevance Heat
Kinase C 9 99.06 Very High Very High Very High
Inflammation 242 95.40 Very High Very High Very High
Central nervous system 64 89.68 High High
alcohol 8 82.96 Quite High
agonist 12 68.52 Quite High
cva 9 5.72 Low Low
Pain 19 5.00 Very Low Very Low Very Low
addiction 17 5.00 Very Low Very Low Very Low
headache 11 5.00 Very Low Very Low Very Low
cytokine 9 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Cancer 1940 99.34 Very High Very High Very High
Breast Cancer 614 98.78 Very High Very High Very High
Metastasis 111 98.40 Very High Very High Very High
Shock 3 96.96 Very High Very High Very High
Diarrhoea 96 96.56 Very High Very High Very High
Exanthema 68 96.00 Very High Very High Very High
Disease 232 95.80 Very High Very High Very High
INFLAMMATION 242 95.40 Very High Very High Very High
Apoptosis 407 89.64 High High
Advanced Or Metastatic Breast Cancer 161 88.60 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Using a panel of 31 human breast tumors, Konecny et al. [41] showed that response to lapatinib was significantly correlated with HER2 expression and its ability to inhibit HER2, Raf, Akt, and ERK phosphorylation.
Phosphorylation (phosphorylation) of HER2 associated with breast cancer
1) Confidence 0.78 Published 2007 Journal Breast Cancer Res Treat Section Body Doc Link PMC2001220 Disease Relevance 0.37 Pain Relevance 0.03
In a preclinical model, lapatinib was shown to inhibit the formation of brain metastases in a breast cancer xenograft mode.32 In this murine model, lapatinib inhibited phosphorylation of EGFR, HER2 and associated downstream proteins.
Phosphorylation (phosphorylation) of HER2 in brain associated with breast cancer and metastasis
2) Confidence 0.76 Published 2010 Journal Cancer management and research Section Body Doc Link PMC3004582 Disease Relevance 1.35 Pain Relevance 0.40
IHC was done using commercially available mouse monoclonal antibodies directed against human ERBB2, FOXA1, phosphorylated ERBB2 (pERBB2), IGF1R, and EGFR (Additionnal file 1-Table S2).
Phosphorylation (phosphorylated) of ERBB2
3) Confidence 0.75 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2958950 Disease Relevance 0 Pain Relevance 0.03
Phosphorylated ERBB2 status was assessed using monoclonal mouse anti-human HER2-pY-1248 with CSA II biotin-free tyramide signal amplification system (DakoCytomation) as described [8].
Phosphorylation (Phosphorylated) of ERBB2
4) Confidence 0.75 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2958950 Disease Relevance 0.06 Pain Relevance 0.04
ERBB2 amplification, gene expression, protein expression and phsophorylation
Phosphorylation (phsophorylation) of ERBB2
5) Confidence 0.75 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2958950 Disease Relevance 0.24 Pain Relevance 0.12
Tyrosine kinase inhibitors, such as emodin, which block HER-2 phosphorylation
Phosphorylation (phosphorylation) of HER-2
6) Confidence 0.69 Published 2009 Journal Journal of Oncology Section Body Doc Link PMC2668926 Disease Relevance 0.70 Pain Relevance 0
IHC was done using commercially available mouse monoclonal antibodies directed against human ERBB2, FOXA1, phosphorylated ERBB2 (pERBB2), IGF1R, and EGFR (Additionnal file 1-Table S2).
Phosphorylation (phosphorylated) of pERBB2
7) Confidence 0.66 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2958950 Disease Relevance 0 Pain Relevance 0.03
The trial is ongoing and biomarker analyses are underway to assess whether EGFR, HER2 or ER phophorylation at Ser118 may predict for benefit from this combination.
Phosphorylation (phophorylation) of HER2
8) Confidence 0.64 Published 2007 Journal Breast Cancer Res Section Body Doc Link PMC2242654 Disease Relevance 0.62 Pain Relevance 0
Furthermore, trastuzumab blocked HER2 heterodimer formation and phosphorylation, reduced ERK1/2 activity, and strongly inhibited cell growth in MCF-7 cells overexpressing EGFR and HER2 and resistant to tamoxifen [18].
Phosphorylation (phosphorylation) of HER2 in MCF-7
9) Confidence 0.60 Published 2007 Journal Breast Cancer Res Treat Section Body Doc Link PMC2001220 Disease Relevance 0.48 Pain Relevance 0.03
A phase I biomarker substudy, in which patients (n = 33) with various tumor types and various lapatinib doses provided a pre-treatment and a sequential Day 21 biopsy, allowed a pilot exploration of the impact of lapatinib on growth and survival pathways.49 Four patients with a PR had ErbB2 overexpression and high pre-treatment expression of phosphorylated (p) ErbB2, which was inhibited by lapatinib.
Phosphorylation (phosphorylated) of ErbB2 associated with cancer
10) Confidence 0.58 Published 2010 Journal Cancer management and research Section Body Doc Link PMC3004582 Disease Relevance 0.74 Pain Relevance 0
IHC was done using commercially available mouse monoclonal antibodies directed against human ERBB2, FOXA1, phosphorylated ERBB2 (pERBB2), IGF1R, and EGFR (Additionnal file 1-Table S2).
Phosphorylation (phosphorylated) of ERBB2
11) Confidence 0.58 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2958950 Disease Relevance 0 Pain Relevance 0.03
Expression of ERBB2, phosphorylated ERBB2, EGFR, IGF1R and FOXA1 proteins was assessed by immunohistochemistry to evaluate the functional ERBB2 status and identify co-expressions.


Phosphorylation (phosphorylated) of ERBB2
12) Confidence 0.58 Published 2010 Journal BMC Cancer Section Abstract Doc Link PMC2958950 Disease Relevance 0.23 Pain Relevance 0
However, resistance to trastuzumab is frequent [6] and its mechanisms are poorly understood [7], although ERBB2 phosphorylation [8], PTEN and PIK3CA status [9] seem important factors.
Phosphorylation (phosphorylation) of ERBB2
13) Confidence 0.58 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2958950 Disease Relevance 0.20 Pain Relevance 0
Expression of ERBB2, phosphorylated ERBB2, EGFR, IGF1R and FOXA1 proteins was assessed by immunohistochemistry to evaluate the functional ERBB2 status and identify co-expressions.


Phosphorylation (phosphorylated) of ERBB2
14) Confidence 0.58 Published 2010 Journal BMC Cancer Section Abstract Doc Link PMC2958950 Disease Relevance 0.23 Pain Relevance 0
M had no effect on HER2 expression level or the degree of phosphorylation, and, when added to 1 ?
Phosphorylation (phosphorylation) of HER2
15) Confidence 0.52 Published 2010 Journal Breast Cancer Res Section Body Doc Link PMC2949655 Disease Relevance 0.41 Pain Relevance 0
g/ml resulted in a moderate decrease in total levels of HER2, and, as expected, a more significant decrease in HER2 activity as reflected by the level of HER2 autophosphorylation.
Phosphorylation (autophosphorylation) of HER2
16) Confidence 0.52 Published 2010 Journal Breast Cancer Res Section Body Doc Link PMC2949655 Disease Relevance 0.48 Pain Relevance 0
The intracellular mechanism of action of lapatinib, in contrast to the extracellular approach of trastuzumab, results in inhibition the phosphorylation of p95HER2.41 PTEN reduction or deficiency results in increased signaling via the critical PI3K/Akt pathway.
Phosphorylation (phosphorylation) of p95HER2
17) Confidence 0.51 Published 2010 Journal Cancer management and research Section Body Doc Link PMC3004582 Disease Relevance 0.20 Pain Relevance 0
Erlotinib inhibited tumour cell proliferation (Ki-67), and phosphorylation of EGFR and HER2.
Phosphorylation (phosphorylation) of HER2 associated with cancer
18) Confidence 0.51 Published 2008 Journal Breast Cancer Res Section Body Doc Link PMC2575526 Disease Relevance 1.31 Pain Relevance 0
Increased phosphorylation of ErbB2(Thr686), ErbB2(Ser1113) and limited phosphorylation of EGFR(Thy845), ErbB2(Tyr1221/1222), ErbB3(Tyr1289) and ErbB4(Tyr1284) sites was seen in the control group.
Phosphorylation (phosphorylation) of ErbB2
19) Confidence 0.41 Published 2009 Journal Mol Cancer Section Body Doc Link PMC2777152 Disease Relevance 0.91 Pain Relevance 0
Increased phosphorylation of ErbB2(Thr686), ErbB2(Ser1113) and limited phosphorylation of EGFR(Thy845), ErbB2(Tyr1221/1222), ErbB3(Tyr1289) and ErbB4(Tyr1284) sites was seen in the control group.
Phosphorylation (phosphorylation) of ErbB2
20) Confidence 0.41 Published 2009 Journal Mol Cancer Section Body Doc Link PMC2777152 Disease Relevance 0.91 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox